Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin and Radiation Therapy in Triple Negative Breast Cancer
NCT02422498Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2015
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cisplatin in triple-negative breast cancer (TNBC), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2015; status: active, not recruiting.
02
Drugs
cisplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02422498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02422498.